ERBB2 and breast carcinoma: SMCC-DM1 was conjugated to an HER2 antibody to generate an anticancer drug, Emtansine (formerly called Trastuzumab-DM1), which has been approved for clinical treatment of invasive HER2-positive breast cancer (21).